普瑞巴林与黛力新治疗持续性躯体形式疼痛障碍的疗效对比
Comparative Study Of Pregabalin And Deanxit In Persistent Somatoform Pain Disorder Patients.
目的：对比观察普瑞巴林和黛力新治疗持续性躯体形式疼痛障碍的疗效。方法：收集持续性躯体形式疼痛障碍患者32例，随机分为普瑞巴林组和黛力新组，分别使用普瑞巴林（最大剂量300mg/天）和黛力新治疗并观察至56天。使用疼痛数字分级法(Numerial rating scale, NRS)评估2组患者在治疗前后的疼痛严重程度，使用Hamilton抑郁量表(Hamilton depression scale, HAMD)和Hamilton焦虑量表(Hamilton anxiety scale, HAMA)评估抑郁焦虑情况，以及世界卫生组织生存质量评定量表进行生存质量评分。结果：普瑞巴林治疗14天及黛力新治疗7天，疼痛严重程度较治疗前有显著改善。普瑞巴林治疗后有效改善患者抑郁焦虑情况以及生存质量。普瑞巴林常见不良反应为头晕、日间嗜睡。结论：普瑞巴林是治疗持续性躯体形式疼痛障碍的安全有效的药物。
Objective: To evaluate the therapeutic effect of pregabalin on persistent somatoform pain disorder compared with deanxit. Methods: Forty cases of persistent somatoform pain disorder were collected and were randomly assigned to a pregabalin group and a deanxit group. Patients in these two groups were administrated with pregabalin or deanxit for 56 days. Numerial rating scale, Hamilton depression scale, Hamilton anxiety scale, and quality of life were evaluated in two groups during treatment. Results: The severity of pain was significantly decreased after treatment of pregarbalin on day 14. Depression, anxiety, and quality of life were also improved. The common side effects included dizziness and somnolence. Conclusion: Pregarbalin is an effective and safe drug for persistent somatoform pain disorder.
李艺、彭英
神经病学、精神病学临床医学
普瑞巴林持续性躯体形式疼痛障碍疼痛
pregabalinpersistent somatoform pain disorderpain
李艺,彭英.普瑞巴林与黛力新治疗持续性躯体形式疼痛障碍的疗效对比[EB/OL].(2013-12-23)[2025-08-04].http://www.paper.edu.cn/releasepaper/content/201312-679.点此复制
评论